A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae173 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Christina A Rostad und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza A Virus, H7N9 Subtype, Vaccines, Inactivated, Antibodies, Viral. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Duke University, Emory University School of Medicine, US Department of Health and Human Services.
Abstract (Originalsprache)
Introduction
A surge of human influenza A(H7N9) cases began in 2016 in China from an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of AS03 adjuvant, prime-boost interval, and priming effects of 2013 and 2017 A(H7N9) IIVs.
Methods
Healthy adults (n = 180), ages 19–50 years, were enrolled into this partially blinded, randomized, multicenter phase 2 clinical trial. Participants were randomly assigned to 1 of 6 vaccination groups evaluating homologous versus heterologous prime-boost strategies with 2 different boost intervals (21 vs 120 days) and 2 dosages (3.75 or 15 μg of hemagglutinin) administered with or without AS03 adjuvant. Reactogenicity, safety, and immunogenicity measured by hemagglutination inhibition and neutralizing antibody titers were assessed.
Results
Two doses of A(H7N9) IIV were well tolerated, and no safety issues were identified. Although most participants had injection site and systemic reactogenicity, these symptoms were mostly mild to moderate in severity; injection site reactogenicity was greater in vaccination groups receiving adjuvant. Immune responses were greater after an adjuvanted second dose, and with a longer interval between prime and boost. The highest hemagglutination inhibition geometric mean titer (95% confidence interval) observed against the 2017 A(H7N9) strain was 133.4 (83.6–212.6) among participants who received homologous, adjuvanted 3.75 µg + AS03/2017 doses with delayed boost interval.
Conclusions
Administering AS03 adjuvant with the second H7N9 IIV dose and extending the boost interval to 4 months resulted in higher peak antibody responses. These observations can broadly inform strategic approaches for pandemic preparedness. Clinical Trials Registration. NCT03589807.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Departments of Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, Houston, Texas, USA.
- Department of Pediatrics and Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
- Center for Vaccine Development, Saint Louis University, St. Louis, Missouri, USA.
- Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
ORCID-Profile: Christina A Rostad
Förderung
- Duke University
- Emory University School of Medicine
- US Department of Health and Human Services
- BARDA
- NIAID NIH HHS
- Children's Healthcare of Atlanta
- NCATS NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Rostad, C. A., Atmar, R. L., Walter, E. B., Frey, S., Meier, J. L., Sherman, A. C., Lai, L., Tsong, R., Kao, C. M., Raabe, V., El Sahly, H. M., Keitel, W. A., Whitaker, J. A., Smith, M. J., Schmader, K. E., Swamy, G. K., Abate, G., Winokur, P., Buchanan, W., …, & Anderson, E. J. (2024). A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae173
Vancouver
Rostad CA, Atmar RL, Walter EB, Frey S, Meier JL, Sherman AC, et al. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae173
BibTeX
@article{Rostad2024,
author = {Rostad, Christina A and Atmar, Robert L and Walter, Emmanuel B and Frey, Sharon and Meier, Jeffery L and Sherman, Amy C and Lai, Lilin and Tsong, Rachel and Kao, Carol M and Raabe, Vanessa and El Sahly, Hana M and Keitel, Wendy A and Whitaker, Jennifer A and Smith, Michael J and Schmader, Kenneth E and Swamy, Geeta K and Abate, Getahun and Winokur, Patricia and Buchanan, Wendy and Cross, Kaitlyn and Wegel, Ashley and Xu, Yongxian and Yildirim, Inci and Kamidani, Satoshi and Rouphael, Nadine and Roberts, Paul C and Mulligan, Mark J and Anderson, Evan J},
title = {A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae173}
}
EUVIMED